Interleukin-1 blockade for recurrent pericarditis: Insights from the real-world experience

The efficacy and safety of anakinra is firmly established in both pediatric and adult populations based upon the results of a randomized trial (AIRTRIP) and an international registry (IRAP).1,2 The study of Caorsi et al raises two important points that should be taken into account when treating patients with recurrent pericarditis.3 First, 25% of pediatric patients were underdosed with first-line medications before commencing anakinra. This highlights the paramount importance of referring these patients to specialized centers.

source https://www.jpeds.com/article/S0022-3476(23)00113-0/fulltext?rss=yes